Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
Total Current Liabilities
Immunoprecise Antibodies Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Total Current Liabilities
CA$6.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Total Current Liabilities
$76.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Total Current Liabilities
CA$11.4k
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Total Current Liabilities
CA$472.1k
|
CAGR 3-Years
52%
|
CAGR 5-Years
24%
|
CAGR 10-Years
-3%
|
|
Immunoprecise Antibodies Ltd
Glance View
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia and currently employs 73 full-time employees. The firm is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The firm offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.
See Also
What is Immunoprecise Antibodies Ltd's Total Current Liabilities?
Total Current Liabilities
6.1m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Total Current Liabilities amounts to 6.1m CAD.
What is Immunoprecise Antibodies Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
12%
Over the last year, the Total Current Liabilities growth was -23%. The average annual Total Current Liabilities growth rates for Immunoprecise Antibodies Ltd have been 12% over the past three years .
